Gland Pharma Appoints Ajay Sahni as CEO of Singapore-Based International Subsidiary
NiveshIQ
NSE: GLAND · Healthcare
Gland Pharma Ltd.
₹3,066.60▼ ₹29.30 (-0.95%)
Price Chart · Daily closes
1Y
6M
3M
1M
1W
1D
⚡ Intelligence Signals
5 active
🟢 Bullish Earnings Catalyst
📊 RS Laggard (5D)
🔄 Sector Sweep
⚡ Signals Aligned
📉 Pullback
NiveshIQ has detected 5 active signals on GLAND. Sign up free to see what each signal means and how it affects the stock.
Unlock signals — freeExpected Move
1D / 1W / 1M range derived from news, fundamentals & technicals
1 Day
±1.8%
1 Week
±4.2%
1 Month
±9.6%
Confidence Score
Based on historical directional & magnitude accuracy for this stock
74
/ 100
About Gland Pharma Ltd.
Gland Pharma Limited, headquartered in Hyderabad, specializes in the manufacturing and sale of injectable formulations across India, the United States, Europe, Canada, Australia, and New Zealand. The company’s core revenue drivers include the production of low‑molecular‑weight heparins, corticosteroids, peptides, and cytotoxic molecules, serving therapeutic areas such as anti‑diabetic, anti‑infective, anti‑neoplastic, and cardiovascular products. In FY27 Q2, Gland Pharma reported a revenue of ₹6,725 crore and a net income of ₹1,129 crore, reflecting steady growth in its contract development and manufacturing organization (CDMO) segment. Recent developments highlight a strategic reset focused on CDMO expansion, which has prompted Nomura to raise its price target to ₹3,750 while maintaining
Financial Highlights
| Metric | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | ₹5,665 Cr +56.29% | ₹5,617 Cr -0.85% | ₹6,431 Cr +14.50% |
| EBITDA Margin | 23.53% | 22.59% | 25.34% |
| Net Profit | ₹772.46 Cr -1.10% | ₹698.53 Cr -9.57% | ₹1,027 Cr +47.07% |
| EPS | ₹46.90 | ₹42.40 | ₹62.35 |
Annual figures in Indian Rupees (Crores). Source: company filings (NSE).
Recent News
Gland Pharma Appoints Ajay Sahni as CEO of Singapore-Based International Subsidiary
Gland Pharma Appoints Ajay Sahni as CEO of Singapore-Based International Subsidiary
🔒
+ 3 more stories about Gland Pharma Ltd.
Full news feed with AI impact summaries, synced in real time.
Sign up free — it's instantStrategic Outlook
- Q1FY27 results: revenue ₹1, 800 Cr, PAT ₹317 Cr, EPS ₹19.23, EBITDA margin 27.2%. Growth context: revenue YoY +19.6%, PAT YoY +47.1%, revenue QoQ +3.3%, PAT QoQ -13.6%. Street verdict: beat, revenue surprise +2.5%, PAT surprise +6.6%.
Management highlights product launches, regulatory approvals, therapy‑mix optimization, order wins, deal pipeline, and b...
FY26 (last completed FY): revenue ₹6, 431 Cr, PAT ₹1, 027 Cr, EBITDA margin 25.3%, EPS ₹62.35. Year-on-year: revenue YoY...
🔒
+ 3 more outlook points
Growth drivers, key risks, and upcoming catalysts — unlocked free.
Sign up free — it's instantMore Healthcare stocks
Everything you unlock with a free account
⚡Intelligence Signals — AI-detected patterns across news, earnings & technicals
📈Price Chart — 1D to 1Y daily closes for GLAND
🎯Expected Move — 1D / 1W / 1M range from news, fundamentals & technicals
🧠Confidence Score — Historical directional & magnitude accuracy for this stock
🎙Analyst Target Price — Consensus target with buy / hold / sell breakdown
📰Full News Feed — All stories synced in real time with AI impact summaries
🔭Strategic Outlook — Growth drivers, risks & upcoming catalysts
📊Watchlist & Portfolio — Track GLAND alongside your other holdings
Unlock full GLAND research — free
No credit card · No trial · Always free to start
Frequently Asked Questions
What AI signals does NiveshIQ provide for Gland Pharma Ltd.?
NiveshIQ detects active intelligence signals for Gland Pharma Ltd. (GLAND) — including earnings catalysts, relative strength patterns, sector sweeps, and pullback setups. It also shows an Expected Move (1D/1W/1M range based on news, fundamentals and technicals) and a Confidence Score based on historical directional and magnitude accuracy. These are exclusive to NiveshIQ.
What are the key financials for Gland Pharma Ltd.?
Gland Pharma Ltd. operates in the Healthcare sector with a market capitalisation of ₹4,152,035.2L Cr. Revenue, net profit, EPS and EBITDA margins across the last three annual periods are shown above, sourced from BSE filings.
Does NiveshIQ provide investment advice?
No. NiveshIQ provides educational market intelligence and research context, not investment advice or buy/sell recommendations.